US Market Report for Ankylosing Spondylitis Immunology Drugs 2018 - MedCore

Thursday, November 16, 2017 Drug News
Email Print This Page Comment bookmark
Font : A-A+

LONDON, Nov. 15, 2017 /PRNewswire/ -- General Report Contents

- Market Analyses include: Unit Sales, ASPs,

Market Value & Growth Trends

Download the full report: https://www.reportbuyer.com/product/5175233

  • Market Drivers & Limiters for each chapter segment
  • Competitive Analysis for each chapter segment
  • Section
    on recent mergers & acquisitions

Treatment options for the AS include medication, exercise, physical therapy and others. In severe cases posture correcting surgery may also be an option. The medication treatment includes nonsteroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, naproxen, and aspirin. If NSAIDs alone do not control inflammation, it may require an injection of corticosteroids directly into the affected joints to bring quick but temporary relief. An injection may be given to the sacroiliac, hip, knee joint, but it is not given in the spine.

In moderate to severe cases the treatment involves disease-modifying antirheumatic drugs (DMARDs), such as methotrexate (Rheumatrex®). Steroid injections into the joint or tendon may be helpful in some cases. Another option includes biologics, such as HUMIRA® (adalimumab), Amjevita™ and Imraldi® (biosimilars to HUMIRA®), CIMZIA® (certolizumab pegol), Enbrel® (etanercept), Erelzi® and Benepali® (biosimilars to Enbrel®), SIMPONI® (golimumab), REMICADE® (infliximab), Inflectra® and Flixabi (biosimilars to REMICADE®), Renflexis® (infliximab-abda) and Cosentyx® (secukinumab). Some of these DMARDs may be used for the treatment of ankylosing spondylitis as well as for other immune disorders, such as psoriasis, rheumatoid arthritis, Crohn's disease, ulcerative colitis and others.

AbstractAnkylosing spondylitis (AS) is a form of arthritis, primarily affecting the spine. AS causes an inflammation in vertebrae and can lead to severe chronic pain and significantly decreases the quality of life. In severe cases the disease can lead to ankylosis -- new bone formation in the spine, causing the spine to fuse in a fixed, immobile position. AS can also affect joints and cause inflammation in shoulders, hips, ribs, heels and others. Sometimes the disease may involve even other organs such as eyes (known as iritis or uveitis) or lungs and heart.

Scope2014-2024

Download the full report: https://www.reportbuyer.com/product/5175233

About Reportbuyer Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers

For more information: Sarah Smith Research Advisor at Reportbuyer.com Email: [email protected] Tel: +44 208 816 85 48 Website: www.reportbuyer.com

View original content:http://www.prnewswire.com/news-releases/us-market-report-for-ankylosing-spondylitis-immunology-drugs-2018---medcore-300556955.html

SOURCE ReportBuyer



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store